Navigation Links
Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
Date:2/19/2013

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, has been invited to participate in Lazard Capital Market's 5th Annual Medical Technology Snowbird Conference. The conference is being held at the Cliff Lodge Snowbird Ski & Summer Resort in Snowbird, Utah from February 27 - March 1, 2013.

Vermillion's Interim CEO Bruce A. Huebner is scheduled to participate in one-on-one meetings with institutional investors to be held throughout the day on Wednesday, February 27, 2013. He will discuss the company's initiatives to drive market adoption of OVA1®, the first FDA-cleared blood test for the pre-surgical diagnosis of ovarian masses using a unique multi-marker algorithm.  

For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your Lazard representative.

About Lazard Capital Markets
Lazard Capital Markets is a growth-oriented full service broker-dealer with a unique position in today's capital markets. The company's institutional clients value its focused, action-oriented proprietary research, which is based on deep domain expertise in the Healthcare, Consumer, Energy, Technology and Transportation sectors. The company's Sales and Trading professionals have long-standing relationships with over 600 institutional accounts, and, with an average of 15 years of experience, have an intimate knowledge of our clients' investment objectives. Finally, the company's relationship with Lazard, an international investment bank, which operates in 39 cities across 21 countries, provides the company with unparalleled global connections. For more information, visit www.lazardcap.com
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. ViroPharma to Participate in Two December Healthcare Investor Conferences
6. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
7. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
8. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
9. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
10. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... (Nasdaq and SWX: BMRN) announced today that AnGes ... Japan, has,received approval for its Marketing Application for ... and Welfare,(MHLW) for the treatment of patients with ... to work with AnGes in bringing the first ...
... Company Cites Important Progress With Needle-free Vaccine Technology and ... Bird Flu ... March 31, 2008, IRVING, Texas, March 31 Carrington,Laboratories, Inc. ... net loss of $9.8 million, or ($0.90) per basic and,diluted share, ...
... Inc. (NYSE: CRY ),(the "Company"), a biomaterials, ... entered into a credit facility with GE Healthcare,Financial ... in revolving,credit for working capital, acquisitions and other ... at which time the outstanding,principal balance will be ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 2CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 3
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... how Listeria monocytogenes, which causes a major ... and hide from the body's immune system. They believe ... , The Listeria bacterium, found in ... undercooked and unpasteurized food, causing flu-like symptoms or gastrointestinal ...
... blood pressure-lowering gene into cells and enables that gene to ... to take gene therapy for the disorder a step closer ... a report released online in the Proceedings of the National ... the leading causes of death and disability in adults worldwide," ...
Cached Biology News:Gene discovery sheds light on causes of rare disease, cancer 2Gene therapy to lower blood pressure just enough 2